Determining the In-Hospital Cost of Bleeding in Patients Undergoing Percutaneous Coronary Intervention

被引:17
作者
Ewen, Edward F. [1 ]
Zhao, Liping [1 ]
Kolm, Paul [1 ]
Jurkovitz, Claudine [1 ]
Fidan, Dogan [2 ]
White, Harvey D. [3 ]
Gallo, Richard [4 ]
Weintraub, William S. [1 ]
机构
[1] Christiana Care Hlth Syst, Ctr Outcomes Res, Newark, DE USA
[2] Sanofi Aventis Res, Global Hlth Outcomes & Market Access, Paris, France
[3] Green Lane Hosp, Dept Cardiol, Auckland 3, New Zealand
[4] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada
关键词
MYOCARDIAL-INFARCTION; BLOOD-TRANSFUSION; FONDAPARINUX; CLOPIDOGREL; ENOXAPARIN; THERAPY; HEPARIN; TRIAL;
D O I
10.1111/j.1540-8183.2009.00431.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The economic impact of bleeding in the setting of nonemergent percutaneous coronary intervention (PCI) is poorly understood and complicated by the variety of bleeding definitions currently employed. This retrospective analysis examines and contrasts the in-hospital cost of bleeding associated with this procedure using six bleeding definitions employed in recent clinical trials. Methods: All nonemergent PCI cases at Christiana Care Health System not requiring a subsequent coronary artery bypass were identified between January 2003 and March 2006. Bleeding events were identified by chart review, registry, laboratory, and administrative data. A microcosting strategy was applied utilizing hospital charges converted to costs using departmental level direct cost-to-charge ratios. The independent contributions of bleeding, both major and minor, to cost were determined by multiple regression. Bootstrap methods were employed to obtain estimates of regression parameters and their standard errors. Results: A total of 6,008 cases were evaluated. By GUSTO definitions there were 65 (1.1%) severe, 52 (0.9%) moderate, and 321 (5.3%) mild bleeding episodes with estimated bleeding costs of $14,006; $6,980; and $4,037, respectively. When applying TIMI definitions there were 91 (1.5%) major and 178 (3.0%) minor bleeding episodes with estimated costs of $8,794 and $4,310, respectively. In general, the four additional trial-specific definitions identified more bleeding events, provided lower estimates of major bleeding cost, and similar estimates of minor bleeding costs. Conclusions: Bleeding is associated with considerable cost over and above interventional procedures; however, the choice of bleeding definition impacts significantly on both the incidence and economic consequences of these events. (J Interven Cardiol 2009;22:266-273).
引用
收藏
页码:266 / 273
页数:8
相关论文
共 20 条
[1]   Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention - Results from the REPLACE-2 trial [J].
Cohen, DJ ;
Lincoff, AM ;
Lavelle, TA ;
Chen, HL ;
Bakhai, A ;
Berezin, RH ;
Jackman, D ;
Sarembock, IJ ;
Topol, EJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (09) :1792-1800
[2]   Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997 [J].
Lauer, MA ;
Karweit, JA ;
Cascade, EF ;
Lin, ND ;
Topol, EJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (08) :924-929
[3]   Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention [J].
Milkovich, G ;
Gibson, G .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (14) :S15-S21
[4]   Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention [J].
Montalescot, Gilles ;
White, Harvey D. ;
Gallo, Richard ;
Cohen, Marc ;
Steg, P. Gabriel ;
Aylward, Philip E. G. ;
Bode, Christoph ;
Chiariello, Massimo ;
King, Spencer B., III ;
Harrington, Robert A. ;
Desmet, Walter J. ;
Macaya, Carlos ;
Steinhubl, Steven R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (10) :1006-1017
[5]   Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery [J].
Moses, JW ;
Leon, MB ;
Popma, JJ ;
Fitzgerald, PJ ;
Holmes, DR ;
O'Shaughnessy, C ;
Caputo, RP ;
Kereiakes, DJ ;
Williams, DO ;
Teirstein, PS ;
Jaeger, JL ;
Kuntz, RE .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (14) :1315-1323
[6]  
RAO AK, 1988, J AM COLL CARDIOL, V11, P1
[7]   Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes [J].
Rao, Sunil V. ;
Kaul, Padma R. ;
Liao, Lawrence ;
Armstrong, Paul W. ;
Ohman, E. Magnus ;
Granger, Christopher B. ;
Califf, Robert M. ;
Harrington, Robert A. ;
Eisenstein, Eric L. ;
Mark, Daniel B. .
AMERICAN HEART JOURNAL, 2008, 155 (02) :369-374
[8]  
Rao SV, 2007, REV CARDIOVASC MED, V8, pS18
[9]   Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes [J].
Rao, Sunil V. ;
Eikelboom, John A. ;
Granger, Christopher B. ;
Harrington, Robert A. ;
Califf, Robert M. ;
Bassand, Jean-Pierre .
EUROPEAN HEART JOURNAL, 2007, 28 (10) :1193-1204
[10]   Heart disease and stroke statistics - 2007 update - A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [J].
Rosamond, Wayne ;
Flegal, Katherine ;
Friday, Gary ;
Furie, Karen ;
Go, Alan ;
Greenlund, Kurt ;
Haase, Nancy ;
Ho, Michael ;
Howard, Virginia ;
Kissela, Bret ;
Kittner, Steven ;
Lloyd-Jones, Donald ;
McDermott, Mary ;
Meigs, James ;
Moy, Claudia ;
Nichol, Graham ;
O'Donnell, Christopher J. ;
Roger, Veronique ;
Rumsfeld, John ;
Sorlie, Paul ;
Steinberger, Julia ;
Thom, as Thom ;
Wasserthiel-Smoller, Sylvia ;
Hong, Yuling .
CIRCULATION, 2007, 115 (05) :E69-E171